Survival improvement for patients with metastatic colorectal cancer over twenty years
2023; Nature Portfolio; Volume: 7; Issue: 1 Linguagem: Inglês
10.1038/s41698-023-00353-4
ISSN2397-768X
AutoresFadl A. Zeineddine, Mohammad A. Zeineddine, Abdelrahman Yousef, Yue Gu, Saikat Chowdhury, Arvind Dasari, Ryan Huey, Benny Johnson, Bryan K. Kee, Michael S. Lee, Maria Pia Morelli, Van K. Morris, Michael J. Overman, Christine M. Parseghian, Kanwal Raghav, Jason Willis, Robert A. Wolff, Yoshikuni Kawaguchi, Jean‐Nicolas Vauthey, Ryan Sun, Scott Kopetz, John Paul Shen,
Tópico(s)Genetic factors in colorectal cancer
ResumoOver the past two decades of successive clinical trials in metastatic colorectal cancer (CRC), the median overall survival of both control and experimental arms has steadily improved. However, the incremental change in survival for metastatic CRC patients not treated on trial has not yet been quantified. We performed a retrospective review of 1420 patients with de novo metastatic CRC who received their primary treatment at the University of Texas M.D. Anderson Cancer Center (UTMDACC) from 2004 through 2019. Median OS was roughly stable for patients diagnosed between 2004 and 2012 (22.6 months) but since has steadily improved for those diagnosed in 2013 to 2015 (28.8 months), and 2016 to 2019 (32.4 months). Likewise, 5-year survival rate has increased from 15.7% for patients diagnosed from 2004 to 2006 to 26% for those diagnosed from 2013 to 2015. Notably, survival improved for patients with BRAF
Referência(s)